How is aHUS diagnosed?

Jul 27, 2023 ... Soliris (eculizumab) has been approved in the European Union (EU) for expanded use to include the treatment of refractory generalised myasthenia ... As anti-C5 therapy like eculizumab is the only treatment for patients with aHUS, optimizing treatment is indispensable. The drug label states that a trough ... This article contains billing and coding guidelines that complement the Local Coverage Determination (LCD) Drugs and Biologicals, Coverage of, for Label and ... ECULIZUMAB (ek yoo LYE zyoo mab) treats certain blood conditions that can cause low levels of red blood cells (anemia) and blood clots. SOLIRIS may lower the ability of your immune system to fight infections. • SOLIRIS increases your chance of getting serious meningococcal infections caused by ... Apr 10, 2019 ... Eculizumab (Soliris®, Alexion Pharmaceuticals, Inc., Boston, MA, USA) ... Soliris (eculizumab) [prescribing information]. Boston, MA ... It is used by specialist doctors to treat two rare conditions called paroxysmal nocturnal haemoglobinuria (PNH) and atypical haemolytic-uraemic syndrome (aHUS). The treatment is given once a week at a dose of 600 mg for the first 4 weeks, then 900 mg every 2 weeks from the fifth week onwards. A few patients require a ... Eculizumab ... Not to be confused with ocrelizumab. Eculizumab, sold under the brand name Soliris among others, is a recombinant humanized monoclonal antibody ... Mar 15, 2025 ... The FDA first approved eculizumab for use in adult patients with generalized myasthenia gravis in 2017, before expanding the indication to ...